Acceleron Pharma Appoints Robert Zeldin Chief Medical Officer

Robert Zeldin has been appointed chief medical officer of Cambridge, MA, drug developer Acceleron Pharma (NASDAQ: [[ticker:XLRN]]). Zeldin joins Acceleron from Belgium-based Ablynx, where he was chief medical officer. Zeldin’s appointment comes as Acceleron and partner Celgene (NASDAQ: [[ticker:CELG]]) prepare to file for FDA approval of the drug luspatercept. The companies have released positive results from late-stage studies testing the drug as a treatment for two blood disorders, myelodysplastic syndrome and beta-thalassemia.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.